Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Date:10/26/2009

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. A Phase 3 clinical trial of MDV3100 in patients with castration-resistant prostate cancer is under way. For more information, please visit us at http://www.medivation.com.

SOURCE Medivation


'/>"/>
SOURCE Medivation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
3. Medivation Announces Pricing of Public Offering
4. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
5. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
6. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
7. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents New Data on Dimebons Novel Mechanism of Action
9. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
10. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):